Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii
- 1 May 1988
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 32 (5) , 755-757
- https://doi.org/10.1128/aac.32.5.755
Abstract
Doses of 200 mg of azithromcyin per kg (body weight) administered by the oral route dialy for 10 days completely protected mice against death caused by intraperitoneal infection with Toxoplasma gondii. The same treatment regimen also protected 80% of mice infected intracerebrally, which suggests that azithromycin attains active concentrations in the inflamed central nervous system.This publication has 11 references indexed in Scilit:
- Effect of roxithromycin on acute toxoplasmosis in miceAntimicrobial Agents and Chemotherapy, 1987
- In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatisAntimicrobial Agents and Chemotherapy, 1987
- Murine Model of Intracerebral ToxoplasmosisThe Journal of Infectious Diseases, 1987
- Toxoplasmosis in immunocompromised patientsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987
- Activity of roxithromycin (RU 28965), a macrolide, against Toxoplasma gondii infection in miceAntimicrobial Agents and Chemotherapy, 1986
- Toxoplasmosis in the Compromised HostAnnals of Internal Medicine, 1976
- Effect of Clindamycin on Acute and Chronic Toxoplasmosis in MiceAntimicrobial Agents and Chemotherapy, 1974
- [Theoretical bases of the prevention by spiramycin of congenital toxoplasmosis in pregnant women].1968
- Inhibition of Folate Biosynthesis and Function as a Basis for ChemotherapyPublished by Wiley ,1965